Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645874 | 0.86 | ALDH1A1 (0.57) | HIF1APOLBMMP1MMP2MMP9 | |
| SCHEMBL4646053 | 0.84 | MMP1 (0.71) | HIF1AMMP1MMP2MMP9MEN1 | |
| SCHEMBL4648540 | 0.84 | MMP1 (0.64) | HIF1AMMP1MMP2MMP9MEN1 | |
| SCHEMBL4648115 | 0.81 | HIF1A (0.51) | HIF1AMMP1MMP2MMP9MEN1 | |
| SCHEMBL4647915 | 0.79 | SMN1; SMN2 (0.56) | HIF1APOLBMMP1MMP2MMP9 | |
| SCHEMBL4647116 | 0.79 | MMP1 (0.57) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4646819 | 0.79 | MAPT (0.54) | HIF1APOLBMEN1KMT2AKDM4E | |
| SCHEMBL4646176 | 0.78 | EGFR (0.62) | HIF1AMMP1MMP2MMP9MEN1 | |
| SCHEMBL4647415 | 0.78 | HIF1A (0.47) | HIF1AMMP1MMP2MMP9MEN1 | |
| SCHEMBL4648657 | 0.77 | EGFR (0.47) | HIF1APOLBMMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410316-B2 | Iminopropene compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20110319437-A1 | IMINOPROPENE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-1957459-A2 | IMINOPROPENE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063702-A2 | IMINOPROPENE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319437-A1 | IMINOPROPENE COMPOUND AND USE THEREOF | IMPA1, INPP5A, CTRL | MGLL 767/4885HIF1A 4805/4885POLB 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.